- Home
- / Blueprint Medicines
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Blueprint Medicines financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$54.8
2023-10-27
Market Capitalization
$3.3 B
2023-10-27
Revenue
$204 M
FY, 2022
CreditSafe Score
?
Score changed on Nov 29, 2023
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|
| Revenue | 66.5M | 793.7M | 180.1M | 204.0M |
| Revenue growth, % | 49.4% | 1093.4% | -77.3% | |
| Cost of goods sold | 425.0K | 17.9M | 17.8M | |
| Gross profit | 793.3M | 162.1M | 186.2M | |
| Gross profit margin, % | 99.9% | 90.0% | 91.3% | |
| General and administrative expense | 96.4M | 157.7M | 195.3M | 237.4M |
| Operating expense total | 427.8M | 484.6M | 804.1M | 714.8M |
| Interest income | 13.7M | 6.6M | 2.4M | |
| Interest expense | 16.8M | |||
| Pre tax profit | 314.9M | (641.1M) | (552.3M) | |
| Income tax expense | 1.1M | 3.0M | 5.2M | |
| Net Income | (347.7M) | 313.9M | (644.1M) | (557.5M) |
| EPS | (7.3) | 5.6 | (11.0) | (9.3) |